Nilo Therapeutics has launched with $101 million in series A funds to drive its ambition to harness neural circuits to restore immune homeostasis. The New York-headquartered company was founded by a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback